Latest carfilzomib Stories
In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been
Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years.
Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.
- The parings of haberdine; also, any kind of fragments.